Two for the price of two: Cubist fronts $1.24b for Trius, Optimer
This article was originally published in Scrip
Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.
You may also be interested in...
Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.